Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RELA | Q04206 | 2/20 | 1.00 |
| ▸ | ACHE | P22303 | 1/20 | 0.71 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.65 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.65 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.65 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.65 |
| ▸ | ESR1 | P03372 | 2/20 | 0.65 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.65 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.65 |
| ▸ | AHR | P35869 | 2/20 | 0.65 |
| ▸ | ABL1 | P00519 | 1/20 | 0.65 |
| ▸ | TTR | P02766 | 1/20 | 0.65 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.65 |
| ▸ | BCR | P11274 | 1/20 | 0.65 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.65 |
| ▸ | NQO2 | P16083 | 1/20 | 0.65 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.65 |
| ▸ | TUBB | P07437 | 1/20 | 0.65 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5496067 | 1.00 | RELA (1.00) | RELAACHETRPA1CYP1A2CYP1A1 | |
| SCHEMBL10097227 | 1.00 | RELA (1.00) | RELAACHETRPA1CYP1A2CYP1A1 | |
| SCHEMBL14947047 | 1.00 | RELA (1.00) | RELAACHETRPA1CYP1A2CYP1A1 | |
| SCHEMBL2622580 | 0.91 | RELA (0.83) | RELAACHETRPA1CYP1A2CYP1A1 | |
| SCHEMBL699458 | 0.90 | RELA (0.81) | RELATRPA1CYP1A2CYP1A1CYP1B1 | |
| SCHEMBL631998 | 0.90 | RELA (0.81) | RELATRPA1CYP1A2CYP1A1CYP1B1 | |
| SCHEMBL14950253 | 0.90 | RELA (0.81) | RELATRPA1CYP1A2CYP1A1CYP1B1 | |
| SCHEMBL4881152 | 0.90 | RELA (0.81) | RELATRPA1CYP1A2CYP1A1CYP1B1 | |
| SCHEMBL13790336 | 0.90 | RELA (0.81) | RELATRPA1CYP1A2CYP1A1CYP1B1 | |
| SCHEMBL699457 | 0.90 | RELA (0.81) | RELATRPA1CYP1A2CYP1A1CYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8980954-B2 | Substituted cis- and trans-stilbenes as therapeutic agents | STC.UNM (US) | 2015-03-17 | — | — | US | claimed |
| CN-114163313-B | Method for selectively synthesizing EZ-stilbene by coupling ruthenium-catalyzed aryl diazonium salt with cinnamic acid | 中山大学 | 2023-11-03 | — | — | CN | disclosed |
| CN-114163313-A | Method for selectively synthesizing EZ-stilbene by coupling aryl diazonium salt and cinnamic acid under catalysis of ruthenium | 中山大学 | 2022-03-11 | — | — | CN | disclosed |
| US-9925153-B2 | Therapeutic agents for skin diseases and conditions | STC.UNM (US) | 2018-03-27 | — | — | US | disclosed |
| US-20160287531-A1 | THERAPEUTIC AGENTS FOR SKIN DISEASES AND CONDITIONS | STC.UNM | 2016-10-06 | — | — | US | disclosed |
| WO-2015085143-A2 | THERAPEUTIC AGENTS FOR SKIN DISEASES AND CONDITIONS | STC.UNM (US) | 2015-06-11 | — | — | WO | disclosed |
| US-8980954-B2 | Substituted cis- and trans-stilbenes as therapeutic agents | STC.UNM (US) | 2015-03-17 | — | — | US | disclosed |
| US-20150034162-A1 | DYE-SENSITIZED SOLAR CELL AND METHOD FOR MAKING SAME | ADEKA CORPORATION (JP) | 2015-02-05 | — | — | US | disclosed |
| US-20150034162-A1 | DYE-SENSITIZED SOLAR CELL AND METHOD FOR MAKING SAME | ADEKA CORPORATION (JP) | 2015-02-05 | — | — | US | disclosed |
| US-8927685-B1 | Thermoset and thermoplastic compositions derived from the essential oils of herbs | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2015-01-06 | — | — | US | disclosed |
| US-20130178536-A1 | SUBSTITUTED CIS- AND TRANS-STILBENES AS THERAPEUTIC AGENTS | STC.UNM (US) | 2013-07-11 | — | — | US | disclosed |
| US-8383831-B2 | Dye for dye-sensitized solar cell, semiconductor electrode, and dye-sensitized solar cell | MITSUBISHI PAPER MILLS LIMITED (JP) | 2013-02-26 | — | — | US | disclosed |
| US-8383831-B2 | Dye for dye-sensitized solar cell, semiconductor electrode, and dye-sensitized solar cell | MITSUBISHI PAPER MILLS LIMITED (JP) | 2013-02-26 | — | — | US | disclosed |
| US-20110155241-A1 | DYE FOR DYE-SENSITIZED SOLAR CELL, SEMICONDUCTOR ELECTRODE, AND DYE-SENSITIZED SOLAR CELL | MITSUBISHI PAPER MILLS LIMITED (JP) | 2011-06-30 | — | — | US | disclosed |
| US-20110155241-A1 | DYE FOR DYE-SENSITIZED SOLAR CELL, SEMICONDUCTOR ELECTRODE, AND DYE-SENSITIZED SOLAR CELL | MITSUBISHI PAPER MILLS LIMITED (JP) | 2011-06-30 | — | — | US | disclosed |
| US-20070249647-A1 | Substituted CIS- and trans-stilbenes as therapeutic agents | REGENTS OF THE UNIVERSITY OF NEW MEXICO | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160287531-A1 | THERAPEUTIC AGENTS FOR SKIN DISEASES AND CONDITIONS | CUTA, TSLP, ELANE | RELA 29/4885ACHE 1540/4885TRPA1 1457/4885 |
| US-20070249647-A1 | Substituted CIS- and trans-stilbenes as therapeutic agents | TGFB1, VHL, TMSB10 | RELA 12/4885ACHE 1869/4885TRPA1 1533/4885 |
| US-20130178536-A1 | SUBSTITUTED CIS- AND TRANS-STILBENES AS THERAPEUTIC AGENTS | PSEN1, TERT, PSEN2 | RELA 10/4885ACHE 47/4885TRPA1 1056/4885 |
| US-20110155241-A1 | DYE FOR DYE-SENSITIZED SOLAR CELL, SEMICONDUCTOR ELECTRODE, AND DYE-SENSITIZED SOLAR CELL | CRY1, CRY2, TYR | RELA 3244/4885ACHE 773/4885TRPA1 378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.